Search
shopping
Search
Menu

Goal and Learning Outcomes

The goal of this program is to provide healthcare professionals with information about Chagas disease, which has been labeled by the Centers for Disease Control and Prevention as one of the five neglected parasitic diseases in the United States. The disease has been targeted for public health action based on the severity of the illness and the number of people infected. The other four neglected parasitic diseases include neurocysticercosis, toxocariasis, toxoplasmosis, and trichomoniasis. After studying the information presented here, you will be able to:
  • Describe the causes, transmission, and symptoms of Chagas disease.
  • Discuss why Chagas disease has become a public health problem in the United States.
  • Explain why most healthcare professionals are unaware of one of the most common causes of congestive heart failure and sudden death in the world.

Course Authors

Accreditation Information

NURSES

In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

 

CEBroker

Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and  West Virginia Board Of Examiners For Registered Professional Nurses

 

Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

 

Disclosures

None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.